CRISPR/Cas9 Edited RAS & MEK Mutant Cells Acquire BRAF and MEK Inhibitor Resistance with MEK1 Q56P Restoring Sensitivity to MEK/BRAF Inhibitor Combo and KRAS G13D Gaining Sensitivity to Immunotherapy

SIMPLE SUMMARY: BRAF inhibitor drug resistance has been a long-time challenge in the treatment of melanoma with BRAF V600E mutation. This study employed the CRISPR/Cas9 technology to generate three isogenic A375 melanoma cell lines with point mutations of NRAS Q61K, KRAS G13D and MEK1 Q56P, respecti...

Descripción completa

Detalles Bibliográficos
Autores principales: Turner, Elizabeth, Chen, Luping, Foulke, John G., Gu, Zhizhan, Tian, Fang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9655013/
https://www.ncbi.nlm.nih.gov/pubmed/36358868
http://dx.doi.org/10.3390/cancers14215449

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9655013/
https://www.ncbi.nlm.nih.gov/pubmed/36358868
http://dx.doi.org/10.3390/cancers14215449

Ejemplares similares